Superficial Esophageal, Gastric or Colorectal LesionsNCT07392268
Validation of AI-ENDO System in Endoscopic Submucosal Dissection
A study testing AI-ENDO system and Conventional ESD in people with Superficial Esophageal, Gastric or Colorectal Lesions, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
This study is a pilot trial designed to evaluate the feasibility and safety of Al-ENDO assisted ESD in patients with gastrointestinal superficial lesions. Patients with gastrointestinal superficial lesions are scheduled for conventional ESD will be screened for eligibility. The study consists of a few stages: 1. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Superficial Esophageal, Gastric or Colorectal Lesions
- What is being tested?
- AI-ENDO system and Conventional ESD
- Type of treatment
- Injection or infusion, Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteHong Kong
- Study dates
- 1 May 2025to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient with superficial esophageal, gastric or colorectal lesions, scheduled for endoscopic submucosal dissection (ESD).
- Age between 18 and 85.
Who cannot join
- Patient who refused to participate.
- Other cases deemed by the examining physician as unsuitable for safe treatment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hong Kong1 site, 1 recruiting
- Recruiting
Department of Surgery, Faculty of Medicine, the Chinese University of Hong Kong
Hong Kong
Hon Chi Yip, MBChB, FRCSEd (General), +85235052956, hcyip@surgery.cuhk.edu.hk
About this study
Official title: Clinical Utility and Validation of Novel AI-ENDO System in Endoscopic Submucosal Dissection
This study is a pilot trial designed to evaluate the feasibility and safety of Al-ENDO assisted ESD in patients with gastrointestinal superficial lesions. Patients with gastrointestinal superficial lesions are scheduled for conventional ESD will be screened for eligibility. The study consists of a few stages:
- In the first phase, the Al-ENDO system will be tested in the background of the ESD procedure prospectively, but without interfering the endoscopists. The Al-ENDO system would be installed in the Endoscopy Centre in Prince of Wales Hospital. Real-time video analysis would be conducted in the background without interference of the endoscopists' performance. A total of 30 clinical ESD procedures would be analysed, with the goal of achieving good accuracy of the system. The data obtained from this group of patients would also serve as control group for comparison with the subsequent procedures with Al-ENDO support.
- The second phase of the study would comprise of a the prospective pilot study which Al-ENDO system would be connected to the endoscopy tower with the auxiliary output monitor placing side-by-side with the endoscopy main monitor. The GUI would be displayed in the auxiliary monitor. This phase aims to demonstrate device and patients' safety throughout the procedure, and a total of 10 patients would be recruited, with the target of ensuring smooth dissection procedure without system interruption of failure. In this phase of the study, only expert endoscopist would be involved in performing the procedure.
- The third phase of the study comprises of a continuation of the initial pilot study with additional of 20 more patients, so that total of 30 procedures would be performed to compare the clinical outcomes with the control group collected previously.
Read the detailed description
Gastrointestinal (GI) cancer, including stomach, colorectal, and esophageal cancer, is collectively the most common cancer worldwide and the leading cause of cancer-related death globally. The disease imposes a significant burden in Hong Kong, with more than 6,000 new cases diagnosed annually according to local cancer statistics. Despite substantial advances in understanding its pathology, molecular mechanisms, and therapeutic strategies, the survival rate of advanced GI cancer remains suboptimal, with a 5-year survival rate below 60% for most malignancies.
The introduction of government-led initiatives and international cancer policies has expanded early GI cancer screening programs, enabling more patients to be diagnosed at an earlier stage. Early detection allows for less-invasive and more effective treatment options with improved prognosis and increased curative surgical rates.
Complete tumor resection remains the only curative approach for localized GI cancer. Endoscopic submucosal dissection (ESD), a minimally invasive endoscopic technique, has become an established method for early-stage cancers confined to the mucosal layer. ESD enables en-bloc resection of lesions, achieving lower local recurrence rates compared with conventional endoscopic mucosal resection. It has also demonstrated favorable perioperative outcomes, including shorter operative time, lower complication rates, and reduced hospital stay. In countries where screening programs are well implemented, such as Japan, the number of ESD procedures now exceeds radical gastrectomies, making ESD the preferred treatment modality for early gastric cancer. ESD is also used for the treatment of pre-malignant lesions in the GI tract, preventing progression to invasive cancer.
An ESD procedure involves four main phases: (1) marking of the targeted lesion, (2) submucosal injection to create a protective cushion, (3) circumferential incision, and (4) submucosal dissection and removal of the lesion. Although ESD enables complete resection of lesions regardless of size and has a recurrence rate below 1%, it remains technically demanding and carries risks such as bleeding and perforation. In regions where ESD adoption is lower, the learning curve may exceed several hundred cases before proficiency is achieved. Increasing international guidance and training efforts have encouraged a global expansion in the use of ESD as its clinical benefits become more widely recognized.
Safe and precise dissection of cancerous tissue within the complex gastrointestinal environment is critical. Medical safety events in surgical practice contribute significantly to excess hospital stays, costs, and mortality. ESD is technically challenging, requiring endoscopists to maintain clear visualization of the submucosal layer while preserving a stable endoscopic field. Anatomical complexities such as colon flexures, thin colonic walls, mucosal folds, and peristalsis further increase the difficulty of colorectal ESD and raise the risk of incomplete dissection and perforation. Given these challenges, there is a clear need for advanced technologies that enhance surgical precision and safety through intelligent intraoperative guidance.
To improve surgical quality and patient safety, it is essential to develop systems that learn from expert experience and surgical outcomes, providing real-time insights that help prevent operative errors. Identification of the correct dissection plane, submucosal vessels, and cutting landmarks contributes to safe and complete tumor removal.
An AI-ENDO integrated platform has been developed by the investigators to assist endoscopists in enhancing the safety and efficiency of ESD procedures. The system incorporates multiple intelligent functions:
- Real-time recognition of ESD surgical phases and performance assessment The AI-ENDO platform analyzes surgical workflow to identify the ongoing procedural phase at each moment. The model was trained on high-quality expert ESD videos collected from Prince of Wales Hospital and externally validated using data from several international centers. The system demonstrated high accuracy, precision, and recall, maintaining consistent performance across datasets. The integrated platform operates with real-time computational efficiency.
- Real-time identification of safe and dangerous zones during ESD The system performs automated segmentation of intraoperative visual fields, identifying anatomic structures such as mucosa, submucosa, muscle layers, and blood vessels. This enables real-time differentiation between safe dissection zones and areas at higher risk for complications. Validation studies using endoscopic surgical videos demonstrated high segmentation accuracy and low latency, with experiments confirming feasibility during live animal trials. AI assistance was associated with shorter procedural time and reduced bleeding events compared with standard procedures of similar complexity.
- Intelligent dissection trajectory guidance using reinforcement learning Reinforcement learning and imitation learning methods were incorporated to predict optimal dissection trajectories based on expert surgical demonstrations. The system analyzes surgical context in real time to provide decision support and trajectory prediction. Testing on extensive video datasets demonstrated improved accuracy and generalization compared with existing trajectory prediction frameworks.
Through the integration of these functions, the AI-ENDO multifunctional platform aims to support intraoperative decision-making, reduce adverse events, and shorten the learning curve for ESD procedures.
The purpose of this study is to evaluate the clinical utility and efficacy of the AI-ENDO system in endoscopic submucosal dissection for early gastrointestinal neoplasia. Technical success, clinical success, and post-ESD adverse events will be systematically assessed.
- Being tested
- AI-ENDO system, Conventional ESD
- Keywords
- Al-ENDO SYSTEM, ENDOSCOPIC SUBMUCOSAL DISSECTION, ESD
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AI-ENDO systemDevice
During procedure of AI-ENDO assisted ESD, the AI-ENDO system will be connected to the video output system of the main endoscopy processor, so that real-time video data could be fed to the AI-ENDO system for AI analysis. In ESD procedures with AI-ENDO assistance, an auxiliary monitor would be placed side-by-side to the main endoscopy output monitor. This enables endoscopist to simultaneously take reference to the AI interpreted videos.
Conventional ESDProcedure or surgery
The ESD procedure would be performed in the same manner as in usual clinical practice. In brief, after identification of the target lesion, submucosal injection will be performed to elevate the submucosal layer from the muscularis propria. Mucosal incision followed by submucosal dissection will be performed using dedicated ESD knives. Countertraction method could be utilized based on the endoscopists' personal preference. After successful resection and ensuring adequate haemostasis, the specimen would be retrieved for pathological evaluation.
| Study group | Role | What they receive |
|---|---|---|
| AI-ENDO assisted ESD | Experimental | ESD performed with AI-ENDO assistance Receives: Device: AI-ENDO system; Procedure: Conventional ESD |
| Conventional ESD | Active comparator | ESD performed as in usual clinical practice Receives: Procedure: Conventional ESD |
What is being measured
The primary outcome is the main question the study is designed to answer.
Technical success rate
Defined as the rate of procedure with successful en-bloc, without major intra-operative adverse event.
Unit of measure: % of procedures
Measured: 1 day
Secondary outcomes (20)
Clinical success rate
Defined as the rate of procedure with pathological R0 resection, without major intra-operative and post-operative adverse event.
Unit of measure: % of procedures
Measured: 30 days
Total procedure time
Time taken from injection to completion of resection. Unit of measure: minutes
Measured: 1 day
Resected lesion size
Size of the resected lesion. Unit of measure: millimeters (mm)
Measured: 1 day
Lesion location
Location of the lesion in the GI tract. Unit of measure: categorical (location)
Measured: 1 day
Lesion histological type
The pathological type of the resected lesion. Unit of measure: categorical (histology)
Measured: 30 days
NASA Task Load Index
Endoscopist's NASA Task Load Index (NASA-TLX) score for the procedure. Score range 0-100, where higher scores means a higher, more demanding perceived workload.
Unit of measure: score (0-100)
Measured: 1 day
Overall rate of intraprocedural adverse events
Rate of all intra-procedural adverse event. Unit of measure: % of procedures
Measured: 1 day
Rate of intraprocedural adverse events - partial thickness muscle injury
Rate of partial thickness muscle injury without full thickness perforation occurring intra-procedure.
Unit of measure: % of procedures
Measured: 1 day
Rate of intraprocedural adverse events - full thickness perforation
Rate of full thickness perforation occurring intra-procedure. Unit of measure: % of procedures
Measured: 1 day
Rate of intraprocedural adverse events - haemorrhage
Rate of major bleeding during procedure causing hemodynamic instability, or require blood transfusion, or causing haemoglobin drop > 2 g/dL.
Unit of measure: % of procedures
Measured: 1 day
Rate of intraprocedural adverse events - Peritonitis
Rate of inflammation of the peritoneum occurring intra-procedure. Unit of measure: % of procedures
Measured: 1 day
Rate of intraprocedural adverse events - others
Rate of any other intra-procedure adverse event. Unit of measure: % of procedures
Measured: 1 day
Overall rate of post-procedural adverse events
Rate of all post-procedural adverse event. Unit of measure: % of patients
Measured: 30 days
Rate of postprocedural adverse events - Electrocoagulation syndrome
Rate of lectrocoagulation syndrome, which is defined as presence of abdominal pain, and fever / leucocytosis after the procedure.
Unit of measure: % of patients
Measured: 30 days
Rate of post-procedure adverse events - delayed haemorrhage
Rate of significant bleeding with haemoglobin drop > 2 g/dL, or causing hemodynamic instability, or require blood transfusion, or requiring re-intervention by endoscopy / surgery.
Unit of measure: % of patients
Measured: 30 days
Rate of post-procedure adverse events - delayed perforation
Rate of delayed perforation occurring after completion of procedure. Unit of measure: % of patients
Measured: 30 days
Rate of post-procedure adverse events - others
Rate of any other adverse events after the procedure. Unit of measure: % of patients
Measured: 30 days
AI-system of latency
Time lag in image interpretation by the AI system at ≥25 frames per second. Unit of measure: milliseconds (ms)
Measured: 1 day
AI system accuracy (pixel accuracy)
Mean pixel-wise accuracy of AI interpretation, expressed as percentage of correctly classified pixels.
Unit of measure: % accuracy
Measured: 1 day
AI system accuracy (Dice similarity coefficient)
Mean spatial overlap between AI-predicted and ground-truth regions (Dice coefficient).
Unit of measure: Dice score (0-1)
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2026
- Study start1 May 2025
- Primary completion30 Jun 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (18)Papers the sponsor has linked to this study.
- Other trials for Superficial Esophageal, Gastric or Colorectal LesionsStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hon Chi Yip, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07392268
- Sponsor's protocol ID
- CRE-2025.198
- Status last verified
- Feb 2026
- First submitted
- 28 Jan 2026
- Last updated
- 6 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
PubMed 33538338Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012 Oct;23(10):2479-2516. doi: 10.1093/annonc/mds236.
PubMed 23012255Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020 Aug 29;396(10251):635-648. doi: 10.1016/S0140-6736(20)31288-5.
PubMed 32861308Nivatvongs S. Surgical management of early colorectal cancer. World J Surg. 2000 Sep;24(9):1052-5. doi: 10.1007/s002680010148.
PubMed 11036281Hasuike N, Ono H, Boku N, Mizusawa J, Takizawa K, Fukuda H, Oda I, Doyama H, Kaneko K, Hori S, Iishi H, Kurokawa Y, Muto M; Gastrointestinal Endoscopy Group of Japan Clinical Oncology Group (JCOG-GIESG). A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer. 2018 Jan;21(1):114-123. doi: 10.1007/s10120-017-0704-y. Epub 2017 Feb 21.
PubMed 28224238Chiu PW, Teoh AY, To KF, Wong SK, Liu SY, Lam CC, Yung MY, Chan FK, Lau JY, Ng EK. Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study. Surg Endosc. 2012 Dec;26(12):3584-91. doi: 10.1007/s00464-012-2371-8. Epub 2012 Jun 8.
PubMed 22678176ASGE TECHNOLOGY COMMITTEE; Kantsevoy SV, Adler DG, Conway JD, Diehl DL, Farraye FA, Kwon R, Mamula P, Rodriguez S, Shah RJ, Wong Kee Song LM, Tierney WM. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc. 2008 Jul;68(1):11-8. doi: 10.1016/j.gie.2008.01.037. No abstract available.
PubMed 18577472Teoh AY, Chiu PW, Wong SK, Sung JJ, Lau JY, Ng EK. Difficulties and outcomes in starting endoscopic submucosal dissection. Surg Endosc. 2010 May;24(5):1049-54. doi: 10.1007/s00464-009-0724-8. Epub 2009 Nov 13.
PubMed 19911227Zhang X, Ly EK, Nithyanand S, Modayil RJ, Khodorskiy DO, Neppala S, Bhumi S, DeMaria M, Widmer JL, Friedel DM, Grendell JH, Stavropoulos SN. Learning Curve for Endoscopic Submucosal Dissection With an Untutored, Prevalence-Based Approach in the United States. Clin Gastroenterol Hepatol. 2020 Mar;18(3):580-588.e1. doi: 10.1016/j.cgh.2019.06.008. Epub 2019 Jun 18.
PubMed 31220645ASGE Standards of Practice Committee; Storm AC, Fishman DS, Buxbaum JL, Coelho-Prabhu N, Al-Haddad MA, Amateau SK, Calderwood AH, DiMaio CJ, Elhanafi SE, Forbes N, Fujii-Lau LL, Jue TL, Kohli DR, Kwon RS, Law JK, Pawa S, Thosani NC, Wani S, Qumseya BJ. American Society for Gastrointestinal Endoscopy guideline on informed consent for GI endoscopic procedures. Gastrointest Endosc. 2022 Feb;95(2):207-215.e2. doi: 10.1016/j.gie.2021.10.022. Epub 2022 Jan 5.
PubMed 34998575Pimentel-Nunes P, Libanio D, Bastiaansen BAJ, Bhandari P, Bisschops R, Bourke MJ, Esposito G, Lemmers A, Maselli R, Messmann H, Pech O, Pioche M, Vieth M, Weusten BLAM, van Hooft JE, Deprez PH, Dinis-Ribeiro M. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. Endoscopy. 2022 Jun;54(6):591-622. doi: 10.1055/a-1811-7025. Epub 2022 May 6.
PubMed 35523224Weingart SN, Iezzoni LI. Looking for medical injuries where the light is bright. JAMA. 2003 Oct 8;290(14):1917-9. doi: 10.1001/jama.290.14.1917. No abstract available.
PubMed 14532322Cuschieri A. Nature of human error: implications for surgical practice. Ann Surg. 2006 Nov;244(5):642-8. doi: 10.1097/01.sla.0000243601.36582.18.
PubMed 17060751Chiu PWY, Yip HC, Xia XF, Chan SM, Ng EKW, Lau JYW. How I do it: Flexible 3-D endoscope for endoscopic submucosal dissection. Dig Endosc. 2019 May;31(3):323-328. doi: 10.1111/den.13315. Epub 2019 Mar 21.
PubMed 30550632Kim ES, Cho KB, Park KS, Lee KI, Jang BK, Chung WJ, Hwang JS. Factors predictive of perforation during endoscopic submucosal dissection for the treatment of colorectal tumors. Endoscopy. 2011 Jul;43(7):573-8. doi: 10.1055/s-0030-1256339. Epub 2011 Mar 29.
PubMed 21448852
Study at a glance
From the registry record, last updated by the sponsor on 6 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Utility and Validation of Novel AI-ENDO System in Endoscopic Submucosal Dissection
- ClinicalTrials.gov ID
- NCT07392268
- Acronym / sponsor ID
- CRE-2025.198
- Keywords
- Al-ENDO SYSTEM, ENDOSCOPIC SUBMUCOSAL DISSECTION, ESD
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 1 May 2025 (actual)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 6 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a pilot trial designed to evaluate the feasibility and safety of Al-ENDO assisted ESD in patients with gastrointestinal superficial lesions. Patients with gastrointestinal superficial lesions are scheduled for conventional ESD will be screened for eligibility. The study consists of a few stages:
- In the first phase, the Al-ENDO system will be tested in the background of the ESD procedure prospectively, but without interfering the endoscopists. The Al-ENDO system would be installed in the Endoscopy Centre in Prince of Wales Hospital. Real-time video analysis would be conducted in the background without interference of the endoscopists' performance. A total of 30 clinical ESD procedures would be analysed, with the goal of achieving good accuracy of the system. The data obtained from this group of patients would also serve as control group for comparison with the subsequent procedures with Al-ENDO support.
- The second phase of the study would comprise of a the prospective pilot study which Al-ENDO system would be connected to the endoscopy tower with the auxiliary output monitor placing side-by-side with the endoscopy main monitor. The GUI would be displayed in the auxiliary monitor. This phase aims to demonstrate device and patients' safety throughout the procedure, and a total of 10 patients would be recruited, with the target of ensuring smooth dissection procedure without system interruption of failure. In this phase of the study, only expert endoscopist would be involved in performing the procedure.
- The third phase of the study comprises of a continuation of the initial pilot study with additional of 20 more patients, so that total of 30 procedures would be performed to compare the clinical outcomes with the control group collected previously.
Detailed description
Gastrointestinal (GI) cancer, including stomach, colorectal, and esophageal cancer, is collectively the most common cancer worldwide and the leading cause of cancer-related death globally. The disease imposes a significant burden in Hong Kong, with more than 6,000 new cases diagnosed annually according to local cancer statistics. Despite substantial advances in understanding its pathology, molecular mechanisms, and therapeutic strategies, the survival rate of advanced GI cancer remains suboptimal, with a 5-year survival rate below 60% for most malignancies.
The introduction of government-led initiatives and international cancer policies has expanded early GI cancer screening programs, enabling more patients to be diagnosed at an earlier stage. Early detection allows for less-invasive and more effective treatment options with improved prognosis and increased curative surgical rates.
Complete tumor resection remains the only curative approach for localized GI cancer. Endoscopic submucosal dissection (ESD), a minimally invasive endoscopic technique, has become an established method for early-stage cancers confined to the mucosal layer. ESD enables en-bloc resection of lesions, achieving lower local recurrence rates compared with conventional endoscopic mucosal resection. It has also demonstrated favorable perioperative outcomes, including shorter operative time, lower complication rates, and reduced hospital stay. In countries where screening programs are well implemented, such as Japan, the number of ESD procedures now exceeds radical gastrectomies, making ESD the preferred treatment modality for early gastric cancer. ESD is also used for the treatment of pre-malignant lesions in the GI tract, preventing progression to invasive cancer.
An ESD procedure involves four main phases: (1) marking of the targeted lesion, (2) submucosal injection to create a protective cushion, (3) circumferential incision, and (4) submucosal dissection and removal of the lesion. Although ESD enables complete resection of lesions regardless of size and has a recurrence rate below 1%, it remains technically demanding and carries risks such as bleeding and perforation. In regions where ESD adoption is lower, the learning curve may exceed several hundred cases before proficiency is achieved. Increasing international guidance and training efforts have encouraged a global expansion in the use of ESD as its clinical benefits become more widely recognized.
Safe and precise dissection of cancerous tissue within the complex gastrointestinal environment is critical. Medical safety events in surgical practice contribute significantly to excess hospital stays, costs, and mortality. ESD is technically challenging, requiring endoscopists to maintain clear visualization of the submucosal layer while preserving a stable endoscopic field. Anatomical complexities such as colon flexures, thin colonic walls, mucosal folds, and peristalsis further increase the difficulty of colorectal ESD and raise the risk of incomplete dissection and perforation. Given these challenges, there is a clear need for advanced technologies that enhance surgical precision and safety through intelligent intraoperative guidance.
To improve surgical quality and patient safety, it is essential to develop systems that learn from expert experience and surgical outcomes, providing real-time insights that help prevent operative errors. Identification of the correct dissection plane, submucosal vessels, and cutting landmarks contributes to safe and complete tumor removal.
An AI-ENDO integrated platform has been developed by the investigators to assist endoscopists in enhancing the safety and efficiency of ESD procedures. The system incorporates multiple intelligent functions:
- Real-time recognition of ESD surgical phases and performance assessment The AI-ENDO platform analyzes surgical workflow to identify the ongoing procedural phase at each moment. The model was trained on high-quality expert ESD videos collected from Prince of Wales Hospital and externally validated using data from several international centers. The system demonstrated high accuracy, precision, and recall, maintaining consistent performance across datasets. The integrated platform operates with real-time computational efficiency.
- Real-time identification of safe and dangerous zones during ESD The system performs automated segmentation of intraoperative visual fields, identifying anatomic structures such as mucosa, submucosa, muscle layers, and blood vessels. This enables real-time differentiation between safe dissection zones and areas at higher risk for complications. Validation studies using endoscopic surgical videos demonstrated high segmentation accuracy and low latency, with experiments confirming feasibility during live animal trials. AI assistance was associated with shorter procedural time and reduced bleeding events compared with standard procedures of similar complexity.
- Intelligent dissection trajectory guidance using reinforcement learning Reinforcement learning and imitation learning methods were incorporated to predict optimal dissection trajectories based on expert surgical demonstrations. The system analyzes surgical context in real time to provide decision support and trajectory prediction. Testing on extensive video datasets demonstrated improved accuracy and generalization compared with existing trajectory prediction frameworks.
Through the integration of these functions, the AI-ENDO multifunctional platform aims to support intraoperative decision-making, reduce adverse events, and shorten the learning curve for ESD procedures.
The purpose of this study is to evaluate the clinical utility and efficacy of the AI-ENDO system in endoscopic submucosal dissection for early gastrointestinal neoplasia. Technical success, clinical success, and post-ESD adverse events will be systematically assessed.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| AI-ENDO assisted ESD | Experimental | Device: AI-ENDO system, Procedure: Conventional ESDESD performed with AI-ENDO assistance |
| Conventional ESD | Active comparator | Procedure: Conventional ESDESD performed as in usual clinical practice |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patient with superficial esophageal, gastric or colorectal lesions, scheduled for endoscopic submucosal dissection (ESD).
- Age between 18 and 85.
Key exclusion criteria (2 listed)
- Patient who refused to participate.
- Other cases deemed by the examining physician as unsuitable for safe treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AI-ENDO systemDuring procedure of AI-ENDO assisted ESD, the AI-ENDO system will be connected to the video output system of the main endoscopy processor, so that real-time video data could be fed to the AI-ENDO system for AI analysis. In ESD procedures with AI-ENDO assistance, an auxiliary monitor would be placed side-by-side to the main endoscopy output monitor. This enables endoscopist to simultaneously take reference to the AI interpreted videos. | Device | AI-ENDO assisted ESD |
| Conventional ESDThe ESD procedure would be performed in the same manner as in usual clinical practice. In brief, after identification of the target lesion, submucosal injection will be performed to elevate the submucosal layer from the muscularis propria. Mucosal incision followed by submucosal dissection will be performed using dedicated ESD knives. Countertraction method could be utilized based on the endoscopists' personal preference. After successful resection and ensuring adequate haemostasis, the specimen would be retrieved for pathological evaluation. | Procedure or surgery | AI-ENDO assisted ESD, Conventional ESD |
Primary outcome
Technical success rate
Time frame: 1 day
Defined as the rate of procedure with successful en-bloc, without major intra-operative adverse event. Unit of measure: % of procedures
20 secondary outcomes
Clinical success rate
Time frame: 30 days
Total procedure time
Time frame: 1 day
Resected lesion size
Time frame: 1 day
Lesion location
Time frame: 1 day
Lesion histological type
Time frame: 30 days
NASA Task Load Index
Time frame: 1 day
Overall rate of intraprocedural adverse events
Time frame: 1 day
Rate of intraprocedural adverse events - partial thickness muscle injury
Time frame: 1 day
Rate of intraprocedural adverse events - full thickness perforation
Time frame: 1 day
Rate of intraprocedural adverse events - haemorrhage
Time frame: 1 day
Rate of intraprocedural adverse events - Peritonitis
Time frame: 1 day
Rate of intraprocedural adverse events - others
Time frame: 1 day
Overall rate of post-procedural adverse events
Time frame: 30 days
Rate of postprocedural adverse events - Electrocoagulation syndrome
Time frame: 30 days
Rate of post-procedure adverse events - delayed haemorrhage
Time frame: 30 days
Rate of post-procedure adverse events - delayed perforation
Time frame: 30 days
Rate of post-procedure adverse events - others
Time frame: 30 days
AI-system of latency
Time frame: 1 day
AI system accuracy (pixel accuracy)
Time frame: 1 day
AI system accuracy (Dice similarity coefficient)
Time frame: 1 day
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Feb 2026.
- Background: PubMed 33538338Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
- Background: PubMed 23012255Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012 Oct;23(10):2479-2516. doi: 10.1093/annonc/mds236.
- Background: PubMed 32861308Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020 Aug 29;396(10251):635-648. doi: 10.1016/S0140-6736(20)31288-5.
- Background: PubMed 11036281Nivatvongs S. Surgical management of early colorectal cancer. World J Surg. 2000 Sep;24(9):1052-5. doi: 10.1007/s002680010148.
- Background: PubMed 28224238Hasuike N, Ono H, Boku N, Mizusawa J, Takizawa K, Fukuda H, Oda I, Doyama H, Kaneko K, Hori S, Iishi H, Kurokawa Y, Muto M; Gastrointestinal Endoscopy Group of Japan Clinical Oncology Group (JCOG-GIESG). A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer. 2018 Jan;21(1):114-123. doi: 10.1007/s10120-017-0704-y. Epub 2017 Feb 21.
- Background: PubMed 22678176Chiu PW, Teoh AY, To KF, Wong SK, Liu SY, Lam CC, Yung MY, Chan FK, Lau JY, Ng EK. Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study. Surg Endosc. 2012 Dec;26(12):3584-91. doi: 10.1007/s00464-012-2371-8. Epub 2012 Jun 8.
- Background: PubMed 18577472ASGE TECHNOLOGY COMMITTEE; Kantsevoy SV, Adler DG, Conway JD, Diehl DL, Farraye FA, Kwon R, Mamula P, Rodriguez S, Shah RJ, Wong Kee Song LM, Tierney WM. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc. 2008 Jul;68(1):11-8. doi: 10.1016/j.gie.2008.01.037. No abstract available.
- Background: PubMed 19911227Teoh AY, Chiu PW, Wong SK, Sung JJ, Lau JY, Ng EK. Difficulties and outcomes in starting endoscopic submucosal dissection. Surg Endosc. 2010 May;24(5):1049-54. doi: 10.1007/s00464-009-0724-8. Epub 2009 Nov 13.
- Background: PubMed 31220645Zhang X, Ly EK, Nithyanand S, Modayil RJ, Khodorskiy DO, Neppala S, Bhumi S, DeMaria M, Widmer JL, Friedel DM, Grendell JH, Stavropoulos SN. Learning Curve for Endoscopic Submucosal Dissection With an Untutored, Prevalence-Based Approach in the United States. Clin Gastroenterol Hepatol. 2020 Mar;18(3):580-588.e1. doi: 10.1016/j.cgh.2019.06.008. Epub 2019 Jun 18.
- Background: PubMed 34998575ASGE Standards of Practice Committee; Storm AC, Fishman DS, Buxbaum JL, Coelho-Prabhu N, Al-Haddad MA, Amateau SK, Calderwood AH, DiMaio CJ, Elhanafi SE, Forbes N, Fujii-Lau LL, Jue TL, Kohli DR, Kwon RS, Law JK, Pawa S, Thosani NC, Wani S, Qumseya BJ. American Society for Gastrointestinal Endoscopy guideline on informed consent for GI endoscopic procedures. Gastrointest Endosc. 2022 Feb;95(2):207-215.e2. doi: 10.1016/j.gie.2021.10.022. Epub 2022 Jan 5.
- Background: PubMed 35523224Pimentel-Nunes P, Libanio D, Bastiaansen BAJ, Bhandari P, Bisschops R, Bourke MJ, Esposito G, Lemmers A, Maselli R, Messmann H, Pech O, Pioche M, Vieth M, Weusten BLAM, van Hooft JE, Deprez PH, Dinis-Ribeiro M. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. Endoscopy. 2022 Jun;54(6):591-622. doi: 10.1055/a-1811-7025. Epub 2022 May 6.
- Background: PubMed 14532322Weingart SN, Iezzoni LI. Looking for medical injuries where the light is bright. JAMA. 2003 Oct 8;290(14):1917-9. doi: 10.1001/jama.290.14.1917. No abstract available.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AI-ENDO system and Conventional ESD in people with Superficial Esophageal, Gastric or Colorectal Lesions, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hon Chi Yip (+852 3505 2956, hcyip@surgery.cuhk.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Technical success rate (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07392268, which also lists 18 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2026.